Janssen Scientific Affairs enrolls 1st patient into Crohn's disease treatment study — 4 insights

Janssen Scientific Affairs enrolled the first patient into its Seavue trial, which aims to compare the effectiveness of Stelara and Humira in treating patients with moderate to severe Crohn's disease.

Here's what you should know:

1. Janssen is conducting the phase 3 trial to create comparative data between the two CD treatment options.

2. Researchers plan to enroll approximately 350 patients into the study, which will take place at up to 100 worldwide sites.

3. The study will conclude in 2020.

4. The treatment phase of the study will take 52 weeks, with a follow-up phase of 76 weeks.

More articles on gastroenterology:
Joint replacement, spine ASC opens in Southern California
Dr. Paul Chin becomes 1st surgeon in Texas to use Catalyst Orthoscience device: 5 takeaways
5 organizations teaming up to tackle antibiotic resistance in outpatient space— 5 notes

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months